Marking of peripheral T-lymphocytes by retroviral transduction and transplantation of CD34+ cells in a canine X-linked severe combined immunodeficiency model
Steven E. Suter(North Carolina State University), Paula S. Henthorn(University of Pennsylvania), Thomas O’Malley(University of Pennsylvania), Mark E. Haskins(University of Pennsylvania), Terry A. Gouthro(University of Pennsylvania), Peter A. McSweeney(Mesoblast (United States)), Peter J. Felsburg(University of Pennsylvania), Brian J. Hartnett(University of Pennsylvania), Peter F. Moore(University of California, Davis)
Cited by 6
Related Papers
Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma
|New England Journal of Medicine|2017|6k
Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1–2 trial
|The Lancet Oncology|2018|2.3k
KTE-X19 CAR T-Cell Therapy in Relapsed or Refractory Mantle-Cell Lymphoma
|New England Journal of Medicine|2020|1.9k